Who are HRS-4642 + AG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inlyta, Cipterbin Combined With Vinorelbine, Icotinib plus WBRT, lorlatinib plus chemotherapy, Anlotinib hydrochloride capsules, imatinib (IM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hrs-4642-ag.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HRS-4642 + AG — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HRS-4642 + AG (HRS-4642 + AG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor VEGFR, FGFR, and related receptor tyrosine kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HRS-4642 + AG (HRS-4642 + AG) — Jiangsu HengRui Medicine Co., Ltd.. HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HRS-4642 + AG TARGET	HRS-4642 + AG	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Tyrosine kinase inhibitor	VEGFR, FGFR, and related receptor tyrosine kinases
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Cipterbin Combined With Vinorelbine	Cipterbin Combined With Vinorelbine	Zhejiang Cancer Hospital	marketed	Tyrosine kinase inhibitor combined with vinca alkaloid	Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine)
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
lorlatinib plus chemotherapy	lorlatinib plus chemotherapy	The First Affiliated Hospital of Guangzhou Medical University	marketed	ALK tyrosine kinase inhibitor (combination therapy)	ALK (anaplastic lymphoma kinase), ROS1
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HRS-4642 + AG — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-4642-ag. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing